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Cross-species transfers of pathogens (zoonoses) cause some of the most virulent diseases, including
anthrax, hantavirus and Q fever. Zoonotic infections occur when a pathogen moves from its reservoir
host species into a secondary host species. Similarly, commensal infections often have a primary
reservoir location within their hosts' bodies from which they rarely cause disease symptoms, but
commensals such as Neisseria meningitidis cause severe disease when they cross into a different body
compartment from their normal location. Both zoonotic and commensal infections cause either mild
symptoms or severe disease, but rarely intermediate symptoms. We develop a mathematical model for
studying three factors that affect the probability of severe disease: the size of the inoculum, the route of
inoculation and the frequency of naturally occurring infections that do not cause symptoms but do
induce protective immunity (vaccinating inoculations). With a single route of infection, increasing
pathogen density causes inoculations to develop more often into disease rather than asymptomatic
vaccinations that provide protective immunity. With two routes of infection, it may happen that a lower
density of a pathogen or of a particular antigenic variant leads to a relatively higher frequency of
disease-inducing versus vaccinating inoculations. This reversal occurs when one route of infection tends
to vaccinate against relatively common pathogens but less often vaccinates against relatively rare
pathogens, whereas the other route of infection is susceptible to disease-inducing inoculation even at
relatively low pathogen density.
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1. INTRODUCTION
Pathogens occasionally infect species that differ from
their normal host. Such cross-species transfers, called
zoonoses, cause some of the most virulent human diseases
(Palmer et al. 1998). For example, anthrax infections typi-
cally arise from carcasses of diseased mammals, and
hantavirus infections come from aerosols of rodent
excreta.
Transmission of zoonotic infections flows from reservoir
populations into the secondary host. In this regard,
zoonoses are similar to commensal infections. A
commensal microbe lives in its host, rarely causing
noticeable symptoms. But some commensals cause a low
frequency of disease when they cross into a different body
compartment from their normal location. For example,
Neisseria meningitidis is a widespread bacterial commensal
of humans that typically colonizes the nasopharynx.
Nearly all infections cause no symptoms. On rare
occasions, the bacteria enter the bloodstream and cross
the blood–brain barrier, causing meningitis (Mims et al.
1993).
In both zoonotic and commensal pathogens, disease-
causing infections form terminal stages that rarely contri-
bute back to the reservoir population. These infection
dynamics free the pathogens from the normal balance
between transmission and virulence (Anderson & May
1982; Ewald 1983) allowing the pathogens to maintain
highly virulent characters in the secondary host or
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atypical body compartment (Levin & Bull 1994; Frank
1996; Holt 1996).
Many zoonotic and commensal pathogens cause either
mild infections or severe disease, but rarely intermediate
symptoms (Palmer et al. 1998). We analyse three factors
that determine the incidence of severe disease from what
are normally very mild infections. First, the frequency of
mild infections influences the proportion of hosts that
gain immunity against subsequent, more severe inocula-
tions. Second, the size of the inoculum affects the
probability that the infection develops into disease or
protective immunity without overt symptoms. Third, the
route of inoculation also affects the probability that an
infection develops into severe disease or asymptomatic,
protective immunity	 for example, airborne, cutaneous
and intestinal inoculations may have different dose–
response curves.
We use mathematical models to show that these three
attributes have important consequences for the dynamics
of zoonotic and commensal infections. With a single route
of infection, increasing pathogen density causes inocula-
tions to develop more often into disease rather than
asymptomatic infections that provide protective immunity
(natural vaccinations). With two routes of infection, it
may happen that a lower density of a pathogen or of a
particular antigenic variant leads to a relatively higher
frequency of disease-inducing versus vaccinating inocula-
tions. This reversal occurs when one route of infection
tends to vaccinate against relatively common pathogens
but less often vaccinates against relatively rare pathogens,
whereas the other route of infection is susceptible to
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pathogen density.
2. BACKGROUND
(a) Definitions
Here we define some of the terms that recur throughout
the paper. Disease-inducing inoculations lead to sympto-
matic infections. Vaccinating inoculations lead to
asymptomatic infections and protective immunity. In our
analysis, vaccinating inoculations are simply small,
naturally occurring inoculations that lead to subclinical
infection and induce immune memory. Seroprevalence is
the frequency of hosts that have antibodies and protective
immunity against a particular pathogen strain. Dosage is
another term for inoculum size.
(b) Zoonotic diseases
Our model depends on three attributes: seroprevalence,
dosage and route of inoculation. For each attribute, we
list a few examples from zoonotic diseases to illustrate the
assumptions of our model. All of our examples come from
Palmer et al.'s (1998) collection of articles on zoonoses.
(i) Seroprevalence
Many zoonotic inoculations cause subclinical infec-
tions. These non-symptomatic cases can be inferred by
study of host antibody titre against the zoonotic parasite's
antigens. Infection rates are of course much higher in
particular human populations or worker groups that live
in close association with the reservoir population.
Relatively high seroprevalence and low rates of clinical
disease have been reported for the following pathogens in
particular subpopulations: Chlamydia psittaci (Caul &
Sillis 1998), Burkholderia pseudomallei (Blue et al. 1998),
Leptospira (Ellis 1998), Lassa virus (Howard 1998),
vesicular stomatitis virus (Morgan-Capner & Bryden
1998), hantavirus (Clement et al. 1998), Rift Valley fever
virus (Swanepoel 1998), yellow fever virus (Monath
1998), Trypanosoma cruzi (Marsden 1998), Leishmania
(Ashford 1998), Cryptosporidium parvum (Coop et al. 1998)
and Toxoplasma gondii (Dubey 1998).
(ii) Dosage
It is well known that increasing numbers of patho-
gens in an inoculation often cause increasingly severe
disease symptoms. For potentially lethal diseases, studies
usually provide the number of pathogens required to
induce death in 50% of hosts (LD 50). Palmer et al.'s
(1998) compilation reports many LD50-values for
different diseases. Those values vary widely among
pathogens and sometimes among different strains of the
same pathogen.
There is less information about the dosage needed to
produce asymptomatic infection with subsequent
protective immunity. Sjogren & Sutherland (1975) showed
that milk from infected cattle provided a low dose of
Mycobacterium tuberculosis sufficient to induce protective
immunity but not disease in most human hosts.
Traditional prevention of Leishmania symptoms in West
Asia was by intentional inoculation of virulent organisms
into a small cut (Ashford 1998). This natural vaccination
prevents disease symptoms in subsequent infections.
Experimental inoculations of Leishmania major into mice
showed dose dependency: low dosage resolved without
symptoms and provided future protection, whereas high
dosage caused disease (Menon & Bretscher 1998).
Our models assume these sorts of dual thresholds, in
which low doses provide asymptomatic infection with
subsequent protective immunity and high doses lead to
disease symptoms. Such dual thresholds for disease are
probably widespread, although not universal.
(iii) Route of inoculation
Many zoonoses cause different symptoms or have
different dose–response patterns depending on route of
inoculation. For example, anthrax produces different
symptoms for cutaneous, pulmonary and intestinal inocu-
lation and different LD50-values have been reported for
cutaneous and pulmonary inoculations (Turnbull 1998).
Repeat symptomatic infections in the same individual are
rare, suggesting that recovery can provide protective
immunity.
Pasteurella is a widespread commensal of animals,
frequently an asymptomatic component of the oral and
pharyngeal flora. Disease apparently occurs most often
by invasion of a wound or following infection by another
pathogen (Barrett 1998).
Coxiella burnetti causes Q fever. Aerosol and cutaneous
inoculation frequently leads to disease. Ingestion of
contaminated milk does not cause disease and sometimes
causes seroconversion (Marrie 1998).
(c) Commensal infections: poultry cellulitis
In poultry cellulitis (Messier et al. 1993; Barnes &
Gross 1997) relatively rare pathogen strains apparently
cause most of the disease. Singer et al. (2000) performed
the following experiment. Forty two-week-old chickens
were put onto a rice hull litter. The litter was inocu-
lated with four strains of Escherichia coli isolated from
cellulitis lesions. The birds also inoculated the litter
with E. coli in their faeces. The distribution of E. coli
strains in the litter was measured by DNA finger-
printing of 96 litter isolates over the following four
weeks. The birds were artificially scratched in week 4
and the scratches were inoculated with swabs that had
been dragged through the litter. The E. coli in the 21
cellulitis lesions that developed were cultured in week 5
and the strain distribution measured.
Rare E. coli strains in the litter caused the majority of
the cellulitis lesions. Given the limited data available,
there are many possible explanations. For example, the
rare strains in the litter may have virulence factors that
enhance success in skin lesions. Alternatively, the
dynamics of immunity may favour rare strains in large,
disease-producing scratches.
Artificial vaccination provides strain-specific protec-
tive immunity (Panigrahy et al. 1984; Gyimah &
Panigrahy 1985; Sandhu & Layton 1985). Thus, the
birds may have developed protective immunity against
the common strains by inoculations through small skin
pricks or scratches, but were less likely to acquire natu-
rally vaccinating inoculations against relatively rare
strains. Our model provides a quantitative framework to
develop this hypothesis for cellulitis and other
commensal infections.Table 1. Parameters of the model
parameter
	
description
A	
age of host
delay between disease-inducing inoculation
and appearance of disease symptoms
delay between vaccinating inoculation and
appearance of protective immunity
v	 rate of vaccinating inoculations; see
equation (10)
6	
rate of disease-inducing inoculations; see
equation (9)
R,	 rate of inoculation by the typically disease- or
lesion-inducing pathway L
Rv	 rate of inoculation by the typically vaccinating
pathway V
DL	 threshold inoculum size to produce disease by
the L pathway
Dv	 threshold inoculum size to produce disease by
the V pathway
PL	 threshold inoculum size for protective
immunity (vaccination) by the L pathway
Pv	 threshold inoculum size for protective
immunity (vaccination) by the V pathway
controls variation in mean inoculation size or
in the frequency of antigenic variants
3. THE MODEL
(a) Disease-inducing versus vaccinating infections
The goal is to calculate the probability that, in an indi-
vidual, a disease-producing inoculation occurs before
protective immunity develops and disease symptoms
appear before age A. Two parameters and two random
variables aid in expressing this probability. Let the para-
meter I be the time required for disease symptoms to
appear after a disease-producing inoculation and the
parameter s be the time required for protective immunity
to develop after an inoculation that leads to asympto-
matic infection. Let the random variable X be the
waiting time until the first inoculation that can lead to
asymptomatic infection and protective immunity and let
the random variable T be the waiting time until the first
inoculation capable of causing disease. Table 1 gives brief
definitions for the main parameters of the model.
If the times and sizes of inoculations occur indepen-
dently, then exponential distributions provide reasonable
models for the waiting time distributions for X and T. In
particular, let v be the rate of vaccinating inoculations and
6 be the rate of disease-producing inoculations. The per-
capita rate of inoculation above a threshold inoculum size
is often referred to as 'the force of infection' (Anderson &
May 1991). Thus, v is the vaccinating force of infection and
6 is the disease-producing force of infection.
The vaccinating force of infection v corresponds to the
probability density of an inoculation being of sufficient
size to cause the first vaccinating infection in an indivi-
dual at a particular point in time x according to the stan-
dard exponential density function
f (x) = ve-vx,	 (1)
as shown, for example, in Anderson & May (1991).
Similarly, the disease-producing force of infection 6
corresponds to the probability density of an inoculation
being of sufficient size to cause the first disease-producing
infection in an individual at a particular point in time  y
according to the standard exponential density function
g(y)	 6e-6Y.	 (2)
The standard forms for the cumulative density functions
are
Pr(X<x) F(x)	 1 —	
(3)
Pr(T <y) G(y)	 1— e-6Y 	 (4)
The key probability is that a disease-producing
inoculation occurs before protective immunity develops
and that disease symptoms appear before age A. This
probability can be expressed in symbols as
--=Pr(T<s± X and r <A—t).	
(5)
If A — i < 5, there is no time for protective immunity to
develop. Thus, the probability of observing disease symp-
toms before age A is simply that a disease-producing
inoculation occurs before A — I, allowing I time-units for
the symptoms to emerge after inoculation. This prob-
ability is G(A 2)	 1 — e-6(A-2 )
If A — I> S, the probability in equation (5) is
A-t-s
G(A	 —F(A—I—s)11+ f G(s+x)f(x)dx. (6)
On the right-hand side, the first part of the sum is the
probability that inoculation leading to symptomatic
infection occurs in time to lead to observed disease, that
is Pr( T < A — I) G(A — -c) and the first inoculation that
would lead to asymptomatic infection and protective
immunity occurs too late to prevent a symptomatic
infection, that is Pr(X > A — i — s) = 1 F (A — s).
The second part of the sum on the right-hand side is the
probability that, over the time-interval (0, A — — s), an
inoculation that could lead to protective immunity
occurs, but an inoculation that leads to asymptomatic
infection occurs before protective immunity can develop.
Standard calculations yield the total probability of
interest as
6e-(v+6)(A-T-s))
v 6
	
(7)
Throughout the derivation, the parameter for age  (A)
and the parameter for time to develop disease symptoms
after a disease-producing inoculation (I) always occur in
combination as A — I. Thus, without loss of generality, we
can drop the parameter I and interpret A as current age
minus time to develop disease symptoms.
An increase in the parameter s, the time to develop
protective immunity after a vaccinating inoculation,
causes an increase in 0, the probability of developing
symptomatic disease. In this article we emphasize the
qualitative effects of various processes on O. Because s has
only a quantitative effect, we will set s 0 to simplify the
following analysis. The simplified form of di from equa-
tion (7) with I s 0 can be written as
1
	 e-6s(v0 	 (1 — e-(v+6)A) 6 
v as
where 1 e-(v+" is the probability that any inoculation
occurs before age A and 5/(v + 6) is the probability that a
disease-inducing inoculation occurs before a vaccinating
inoculation. For large values of A, the probability 0
approaches 5/(v + 6).
(b) Rates of inoculation
In this model, pathogens can enter hosts by two different
routes. The first pathway often leads to disease, but a low
infecting dose causes asymptomatic infection that provides
immune protection against later inoculations. The second
route of inoculation typically develops into an asympto-
matic infection and subsequent immune protection, but a
high infecting dose causes disease. We use the subscript L
for the pathway of inoculation that typically produces a
lesion or disease, and the subscript V for the pathway of
inoculation that typically vaccinates or is asymptomatic.
We assume that the number of pathogens (dosage) in
each inoculation follows an exponential distribution. If
the mean number of pathogens entering the host for a
particular pathway of inoculation is qp,, then the
probability that the number of pathogens is greater than
a threshold k is e-klqi". We have split the mean into two
parts: ,u, is the base-level mean and 0 < q 1 is a para-
meter that controls inoculation density. The parameter q
can represent either variation in total inoculation density
or the frequency of different antigenic variants. Note that
the exponential distribution allows one to express the
probability of being above a threshold in a scale-free way
with respect to the mean, that is kl,u is the value of the
threshold relative to the maximum value of the mean.
The course of an individual's lifetime with regard to
asymptomatic or disease-causing inoculations depends on
the rates at which such inoculations occur. For a given
inoculation in the typically disease- or lesion-producing
pathway (L) the threshold number of pathogens required
to cause disease is /3L and the expected (mean) number of
pathogens per inoculation is EL. For this pathway of inocu-
lation, we can express the threshold for disease relative to
the mean as DL = /3L /EL. Likewise, for the L pathway the
threshold number of pathogens required to cause asympto-
matic infection and subsequent immune protection is aL
and the expected (mean) number of pathogens per inocu-
lation is EL. Thus, the threshold for immune protection
relative to the mean is PL ceLIEL. (See table 1 for brief
definitions of the key threshold parameters.)
The typically vaccinating route of infection (V) has
analogous thresholds for disease-causing inoculations or
protective inoculations. The expected number of patho-
gens entering by this route is Ev. The disease threshold
relative to the mean is Dv = OvIEv, where /3v is the
threshold number of pathogens for causing disease by the
typically vaccinating route. The protective threshold
relative to the mean is Pv = av/Ev, where av is the
threshold number of pathogens for causing asymptomatic
infection and subsequent protection by the typically vacci-
nating route. For both pathways a < and inoculations
less than a do not cause disease or protective immunity.
These definitions lead to four important probabilities:
CD"' /q, the probability of being above the disease
threshold in the L pathway; e-PL /q, the probability of
being above the threshold for asymptomatic infection and
immune protection for the L pathway; e -Dv lq, the
probability of being above the disease threshold in the V
pathway; and e-Pv/q, the probability of being above the
threshold for asymptomatic infection and immune
protection for the V pathway. The parameter q controls
the total pathogen density or the relative density of a
particular antigenic variant.
The rates of inoculation by the L and V pathways are
RL and Rv. Thus, the total rate of disease-inducing inocu-
lations by both pathways is
6 RLe-Daq ±Rve-DvIg.
The total rate of effectively vaccinating inoculations that
lead to asymptomatic infection and subsequent immune
protection is
= RL (e
-PL/q _ /\ e	 Rv(e-Pvlq e-Dvlq),
where the subtracted probabilities remove cases in which
inoculations are above the disease-inducing thresholds.
The rates 6 and v can be used in equations (7) and (8) in
order to calculate the probability that an individual
receives a disease-inducing or vaccinating inoculation by a
particular age A. Table 1 lists the parameters of the model.
4. DOSAGE AND A SINGLE ROUTE OF INFECTION
When there is only a single route of infection,
increasing the average dosage increases the probability of
developing symptomatic infection. We show this by
reducing the result in equation (7) for two routes of
infection to a special case in which there is only one route.
To accomplish this reduction, we set the rates and thresh-
olds for each pathway to be the same. This makes the
pathways equivalent, in effect producing a total infection
process with a twofold increase in rate relative to infection
by each pathway.
The processes for the two pathways L and V can be
made equivalent by setting RL Rv = R, DL  Dv = D
and PL = Pv = P. With these assumptions 6 =2Re-DIq
and v + 6 = 2Re-PIq, where variations in q control the
average dosage per inoculation. Substituting into
equation (8) shows that the probability of symptomatic
disease	 increases with average dosage per inoculation
q. As age A increases to large values,	 approaches
6I(v ± 6) 	 e-(D-P)Iq.
5. INTERACTION OF DOSAGE AND ROUTE
OF INFECTION
Different routes of infection can reverse the typically
increasing relationship between pathogen density and
disease. With two routes of infection, it may happen that a
lower density of a pathogen or of a particular antigenic
variant leads to a relatively higher frequency of disease-
inducing versus vaccinating inoculations. This reversal
occurs when one route of infection tends to vaccinate
against relatively common pathogens but less often
vaccinates against relatively rare pathogens, whereas the
other route of infection is susceptible to disease-inducing
inoculation even at relatively low pathogen density.
(8)
(9)
(10)(b) (d)
4
3
2
1
0
1
2
0
(a) (c)
4
3
2
1
0
1
2
inducing inoculations occur by the typically lesion- or
disease-inducing route of infection, that is RLe-DL iq
>> Rve-Dv /q. This allows us, as an approximation, to drop
the right term of the sum in the numerator, giving the rela-
tive frequency of disease-inducing inoculations as 
1 
(12)
v 6 — e(DL-Polq	 (RvIRL)e-(Pv-DL)Iq '
with the four parameters DL PL, Pv DL, RvIRL and
q.
What conditions must be met for the relative frequency
of disease-inducing inoculations to increase as the total
density of the pathogen q decreases? We can examine this
question by studying the two terms in the denominator of
equation (12).
For the first term e(DL-PL)/q, note that DL PL
because the threshold for a disease-inducing inoculation
by the L pathway DL must be greater than or equal to
the threshold for a protective or vaccinating inoculation
by the L pathway PL. Thus, a decline in q means that
e(DL-PL)/q increases and 6I (v + 6) declines. This term
cannot explain how declining q increases the relative
frequency of disease-producing inoculations.
The second term can counteract the effects of the first
only if e-(Pv-DL)/q declines with decreasing q. This
requires Pv > DL, that is Pv, the threshold number of
pathogens to induce vaccinating protection relative to
the average number of pathogens inoculated by the V
pathway, must be greater than DL, the threshold number
of pathogens to cause disease relative to the average
number of pathogens inoculated by the L pathway. If
DL . PL, then Pv > DL is a necessary and sufficient
condition for 6I(v ± 6) to increase with declining q in
equation (12). If DL >PL, then Pv>DL is a necessary
DL-PL= 0.0
	
DL-PL= 0'01
–2	 –1	 –2
log(q)
	
log(q)
Figure 1. Rates of vaccinating and disease-causing inoculations and consequences for disease. The top panels show the rates of
vaccinating (v) and disease-causing (6) inoculations as functions of the density of pathogens q. All quantities are on a logio scale.
The rates are calculated from equations (9) and (10) with  S	 = 0, Dv = oo, RL = 1, Rv = 104, DL = 0.02, Pv DL = 0.1 and
DL PL given above each panel. The bottom panels plot 6/(v + 6), the relative frequency of first inoculations that lead to disease
symptoms rather than non-symptomatic, protective immunity.
Many of the parameters in table 1 influence the	 simplifying assumption. Assume that most disease-
frequency of disease-inducing versus vaccinating inocu-
lations. This large parameter space requires a step-by-
step approach to building a picture of the interactions
between various processes. We begin with the relative
frequencies of individuals that have experienced either a
vaccinating or disease-inducing inoculation. This relative
frequency is independent of age, depending only on the
rates at which vaccinating or disease-inducing inocula-
tions occur.
The relative frequencies of vaccinating or disease-
inducing inoculations provide important information, but
do not tell the whole story. For example, vaccinating
inoculations may be relatively more common early in life,
but the total frequency of inoculations may be low. As age
increases, the relative frequency of first inoculations that
induce disease may increase as the probability of any
inoculation rises.
(a) Relative frequencies of symptomatic
and vaccinating inoculations
Recall that, over all routes of infection, 6 is the total
rate of disease-inducing inoculations and v is the total
rate of vaccinating inoculations. At any age, the relative
frequency of first inoculations that lead to disease is
6I (v + 6), assuming, as discussed above, that s = 0. With
the definitions in equations (9) and (10), this relative
frequency is
6	 Ris-Daq Rve-Doq
v 6 RLe-PL/q Rve-Pv/q
This value depends on seven parameters, which makes
study difficult.
The interesting qualitative features of the model can be
made clearer by reducing the parameters with aDL —PL = D —P =002 L L D —P = 0.1 L L
Figure 2. The relative frequency of disease-inducing inoculations for various parameter combinations. Plots are based on
equation (12). A decrease in DL — PL lowers the dominant value of pathogen density q. An increase in Pv DL raises the
frequency of disease-inducing inoculations. In all plots s = T = 0 and Dv = oc. For the top row, Pv — DL = 0.02; for the bottom
row, PV —DL = 0.1.
S = 0.2	 = 1
	
S = 5
Figure 3. Accumulation of symptomatic infections with increasing age  A. The probability of symptomatic infection at a
particular age is given by 0 in equation (7) using (5 and v from equations (9) and (10). In all plots s = T 0 and Dv = oc. Age A
can be measured on any time-scale, with the average number of inoculations at age A given by RLA = 0.002A and RA = 2A for
the L and V routes of infection. The ratio of inoculation rates by different routes is log(Rv/R L) = 3. The parameter S provides a
scaling factor for the remaining parameters with PL = 0.01S, Pv = 0.08S and DL = 0.02S.
condition, but the net outcome depends on the balance
between the processes given by the two terms in the
denominator of equation (12).
Figure 1 illustrates how different routes of infection can
cause relatively rare pathogens to inflict more disease
than relatively common pathogens. In figure la, at low
pathogen density the rate of disease-causing inoculations
(5 is higher than the rate of vaccinating inoculations  v. As
pathogen densities increase, v rises above 6. The relative
changes of v and (5 cause the frequency of disease-causing
inoculations 6/ (ii + 6) to decrease as pathogen density
rises (figure lb). In figure la,b, the L route of infection has
the same threshold for disease as for vaccination,
DL — PL = 0. When DL >PL, a more complex pattern
arises (figure lc), leading in that example to a maximum
relative frequency of disease-causing inoculations at a
pathogen density of approximately log( 2) = 0.01.
If there exists a pathogen density that causes a local
maximum in the relative frequency of disease-causing
inoculations, as in figure ld, that pathogen density is
given by
PV PL
This equation shows the qualitative effects of various
parameters on q*  For example, q* declines with a
decrease in Pv PL or DL — PL. A rise in either Rv IRL
or Pv DL also causes a decline in q* . Figure 2 illustrates
these trends for a few parameter combinations.
(b) Total frequencies at various ages
The relative rates of vaccinating and disease-inducing
inoculations provide only partial information about
q =
ln(Rv/R ) ln(13v —DL)	 (DL PL) •
(13)disease incidence. Consider, for example, the lower-left
panel of figure 2 with a high Rv:RL ratio. A low pathogen
density q causes a high relative frequency of disease-indu-
cing inoculations, whereas a high pathogen density causes
a low relative frequency of disease-inducing inoculations.
However, the total rate of inoculations declines as
pathogen density decreases. The way in which disease-
inducing inoculations arise over an individual's lifetime
depends on both the relative frequency of disease-
inducing inoculations and the total rate of inoculations.
Figure 3 illustrates the accumulation of disease-
inducing inoculations over the lifetimes of individuals.
The height of each plot is the probability 0 that an
individual will have symptomatic disease before age A.
We describe the details of the parameters in the figure
legend. Four conclusions follow.
First, advancing age causes a decline in the pathogen
density that causes the peak probability of disease. This
decline occurs because a lower pathogen density causes a
lower total rate of inoculation.
Second, the surfaces in figure 3 are insensitive to the
parameter PL, given that DL PL. This insensitivity
occurs because most protective immunity arises from the
typically vaccinating route of infection V.
Third, the scaling of DL and Pv by S determines the
pathogen density that yields the maximum probability of
disease. This scaling occurs because the rates of disease-
inducing and vaccinating inoculations are dominated by
the values of DLIq and Pvlq. Thus, multiplying both DL
and Pv by a factor S requires rescaling pathogen density
to Sq to obtain an invariant effect.
Fourth, the difference S(Pv—DL) affects the height but
not the location of the surfaces in figure 3 when holding  S
constant. This pattern, which is not shown in figure 3, is
similar to the change between the rows of plots in figure 2.
6. CONCLUSIONS
We analysed three factors that influence the probability
of severe disease in zoonotic and commensal infections:
the size of the inoculum, the route of inoculation and the
frequency of naturally occurring vaccinating inoculations.
With a single route of infection, rising pathogen density
increases the cases of disease. Two routes of infection can
reverse this trend. Reversal occurs when one route of
infection tends to vaccinate against relatively common
pathogens but less often vaccinates against relatively rare
pathogens, whereas the second route of infection causes
disease-inducing inoculations even at relatively low
pathogen density (figure 1).
We designed the models to highlight pathogen density q
as a key parameter in the analysis of infection and
disease. We have interpreted q as the maximum pathogen
density that can occur, with variations in q over the
interval [0,1]. Given this set-up, we can also interpret q as
the frequency of antigenically distinct strains of the
pathogen, that is, strains that do not provide cross-reac-
tive immune protection. Thus, from figure 3, an antigenic
variant at low frequency (low q) may be responsible for
the majority of disease symptoms.
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